Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nuwellis ( (NUWE) ) has provided an announcement.
On June 27, 2025, Nuwellis, Inc. appointed John L. Erb as the Chief Executive Officer and President, solidifying his leadership role after serving as interim CEO since February 2025. Mr. Erb, who has a long history with the company and extensive experience in the medical device sector, will continue to serve as Chairman of the Board. Additionally, the company announced a one-for-forty-two reverse stock split, approved by the board on June 19, 2025, to be effective on July 3, 2025, which aims to consolidate shares and adjust the stock’s market value, impacting shareholders and the company’s trading dynamics.
The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Spark’s Take on NUWE Stock
According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.
Nuwellis is struggling with financial and valuation challenges, reflected in its low scores. The potential Nasdaq delisting adds risk, although strategic shifts and agreements could provide future opportunities. The stock’s technical indicators show bearish momentum, highlighting significant near-term risks.
To see Spark’s full report on NUWE stock, click here.
More about Nuwellis
Nuwellis, Inc. operates in the medical device industry, focusing on the development, manufacturing, and distribution of devices for treating heart-related conditions, including congestive heart failure. The company is known for its Aquadex™ system and has a market focus on innovative medical solutions for cardiovascular health.
Average Trading Volume: 10,203,370
Technical Sentiment Signal: Sell
Current Market Cap: $1.11M
For an in-depth examination of NUWE stock, go to TipRanks’ Overview page.